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ABSTRACT 
Objectives: To determine whether the process of ubiquitination and/or activity of the 26S 
proteasome are involved in the induction of osteoarthritis (OA). 
Methods:  Bovine cartilage resorption assays, chondrocyte cell-line SW1353 and primary 
human articular chondrocytes were used with the general proteasome inhibitor MG132 or 
vehicle to identify a role of the ubiquitin–proteasome system (UPS) in cartilage destruction 
and matrix metalloproteinase-13 (MMP13) expression. In vivo, MG132 or vehicle, were 
delivered subcutaneously to mice following destabilisation of the medial meniscus (DMM) 
induced OA. Subsequently, DMM was induced in Lys-to-Arg (K48R and K63R) mutant 
ubiquitin (Ub) transgenic mice. Cytokine-signalling in SW1353s was monitored by 
immunoblotting and novel ubiquitinated substrates identified using Tandem Ubiquitin 
Binding Entities purification followed by mass spectrometry.  The ubiquitination of TRAFD1 
was assessed via immunoprecipitation and immunoblotting and its role in cytokine signal-
transduction determined using RNA interference and real-time RT-PCR for MMP13 and 
interleukin-6 (IL6). 
Results:  Supplementation with the proteasome inhibitor MG132 protected cartilage from 
both cytokine-mediated resorption and degradation in vivo in mice following DMM-induced 
OA. Using transgenic animals only K48R-mutated Ub partially protected against OA 
compared to wild-type or wild-type Ub transgenic mice and this was only evident on the 
medial femoral condyle. After confirming ubiquitination was vital for NF-κB signalling and 
MMP13 expression, a screen for novel ubiquitinated substrates involved in cytokine-
signalling identified TRAFD1; the depletion of which reduced inflammatory mediator-
induced MMP13 and IL6 expression. 
Conclusions:  Our data for the first time identifies a role for ubiquitination and the 
proteasome in the induction of OA via regulation of inflammatory mediator-induced 
MMP13 expression. These data open avenues of research to determine whether the 
proteasome, or K48-linked ubiquitination, are potential therapeutic targets in OA. 
 
Keywords 
Ubiquitin, proteasome, osteoarthritis, animal model, MMP13 
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INTRODUCTION 
 
Osteoarthritis (OA) is the most prevalent joint disease,[1] the typifying feature of which is 
the progressive degradation of articular cartilage.[2] Cartilage itself is composed of an 
extracellular matrix (ECM) rich in proteoglycan (principally aggrecan) and collagen (mainly 
type II) maintained by the sole cell type, the chondrocyte. Remodelling and turnover of this 
ECM in normal physiology is mediated through the regulation of the expression of matrix 
components and matrix-degrading enzymes, the metalloproteinases.[3] The phenotype of 
the chondrocytes shifts in OA, through as yet unidentified processes, to favour catabolism 
with an increase in metalloproteinase expression evident. Matrix metalloproteinase (MMP)-
13 is the generally accepted type II collagen-degrading proteinase in OA with pathological 
aggrecan cleavage mediated by ADAMTS enzymes, most probably ADAMTS-5.[4] 
Mechanisms to alter the expression of these enzymes in OA are potential therapeutic 
targets in what is currently a disease only treatable by joint replacement surgery.  
 
Cellular proteins exist in a dynamic state with multiple pathways leading to their 
degradation, the best characterised being the ubiquitin–proteasome system (UPS). The UPS 
plays a pivotal role in the degradation of proteins important in numerous cellular processes 
including signal transduction pathways, a notable example being that of the NF-κB pathway 
via the regulation of IκB degradation. IκBs normally bind and sequester NF-κB dimers in the 
cytoplasm, but following their degradation the NF-κB complex translocates to the nucleus 
and regulates inflammatory signalling.  Like most proteins destined for degradation via the 
UPS, IκB is covalently modified by the attachment of the small polypeptide ubiquitin (Ub). 
Subsequently, additional Ub polypeptides can be covalently attached to the first Ub to 
create a poly-Ub chain that eventually directs the client protein for proteasomal 
degradation.[5, 6]  
 
Ub itself is a highly-conserved 76 amino acid polypeptide expressed by all eukaryotes. The 
covalent attachment of Ub to cellular proteins, ubiquitination, occurs at lysine (K) residues. 
Ub itself contains seven K residues which allows for different poly-Ub chains to be 
generated including K48 chains which target proteins to the proteasome. K63 and linear Ub 
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chains have emerged as having important roles in signal transduction pathways, the most 
studied again being the NF-κB pathway.[6]  
 
The aim of this study was to investigate the role of Ub and the UPS in the induction of OA in 
a murine model and to identify novel targets of Ub, all of which may have potential 
therapeutic relevance.  
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METHODS  
 
Cells, samples and treatments 
This study was performed with Ethical Committee approval from the Newcastle and North 
Tyneside Health Authority, UK. Human articular chondrocytes (HACs) were from consenting 
patients undergoing knee joint replacement surgery and were isolated and cultured as 
described.[7] Human chondrosarcoma cells (SW1353) were cultured as described.[8] Cells 
were seeded one day before treatment and cultured in serum-free medium overnight prior 
to stimulation. Cells were stimulated with human recombinant IL-1α (0.5 ng/ml) or 0.5 
µg/ml poly(I-C) (Invivogen, Source BioScience LifeSciences, Nottingham, UK). Where 
indicated, cells were treated 1 h before and during stimulation with MG132 (5 µg/ml) (Tocris 
biosciences, R&D Europe Ltd. Abingdon, UK or Sigma-Aldrich Ltd. Poole, UK). 
 
Gene depletion/RNA intereference (RNAi) 
Cells were transfected with siRNA (50 nM) for 48 h using Dharmafect 1 (Dharmacon, Thermo 
Fisher Scientific, Epsom, UK) according to the manufacturer’s protocol and as described 
previously.[7, 8] The following siRNAs were used: siGENOME SMARTpool: siGenome TRAFD1 
siRNA (M-004097-01-0005) and siGenome Non-targeting siRNA pool #2 (D-001206-14-
20)(siCon)(Dharmacon). 
 
Immunoblotting 
Whole cell lysates were prepared as described but supplemented with 20 mM N-
ethylmaleimide, to block deubiquitination.[7] Protein extracts were separated by SDS-PAGE, 
transferred to PVDF or nitrocellulose membranes and probed with the following antibodies: 
anti-IκBα; anti-phospho-NF-κB p65; anti-FLAG (Cell Signaling, New England Biolabs (UK) Ltd, 
Hitchin, UK); anti-GAPDH (Chemicon, Millipore (U.K.) Ltd., Watford, UK); anti-TRAFD1 (Santa 
Cruz Biotechnology (SCBT), Inc., Insight Biotechnology Ltd., Wembley, UK), and anti-
Ubiquitin (Dako UK Ltd, Ely, UK). 
 
Enrichment of proteins with Tandem Ubiquitin Binding Entities (TUBES) 
SW1353 protein extracts were prepared following 30 min stimulation with IL-1, 1 h 
stimulation with poly(I-C), or under basal conditions, all in presence of MG132. Cell lysis 
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buffer (50 mM Tris-HCl pH 7.5, 0.15 M NaCl, 1 mM EDTA, 1% NP40, 10% glycerol) was 
supplemented with protease inhibitor cocktail (Sigma-Aldrich) and 20 mM N-
ethylmaleimide, and concentrated with a 9 kDa cut-off filter (Pierce, Thermo Fisher 
Scientific). 4.5 mg of protein were pre-cleared with 50 µl 50% slurry of control agarose for 
30 min, and then incubated with 200 µl of 50% slurry TUBE 2 (tebu-bio Ltd, Peterborough, 
UK) overnight at 4
o
C.[9] Enriched proteins were washed thrice with TBS-T (20 mM Tris-HCl 
pH 8.0, 0.15-0.2 M NaCl, 0.1% Tween-20), eluted with 200 µl 0.2M glycine-HCl pH 2.5 and 
concentrated with a 10 kDa cut-off filter (Amicon, Millipore, Thermo Fisher Scientific, 
Epsom, UK). Enrichment of ubiquitinated polypeptides was visualised by immunoblotting 
prior to being reduced with 1 mM DTT, alkylated with 5 mM chloroacetamide, and trypsin 
(Promega, Southampton, UK) digested at 37
o
C overnight before identification by mass 
spectrometry (MS). 
 
Mass spectrometric analysis and data analysis 
MS was performed by Dundee Cell Products Ltd. (Dundee, UK) on an UltiMate™ 3000 nLC 
(Thermo scientific) coupled to a LTQ Orbitrap XL (Thermo Scientific). RAW data files were 
extracted with Raw2MSM and searched using Mascot Search Engine. A maximum of 2 
missing tryptic cleavages and the following modifications were selected for database search 
criteria: fixed modifications: Carbamidomethyl (C); variable modifications: Acetyl (N-term), 
Dioxidation (M), Gln->pyro-Glu (N-term Q), Oxidation (M), with/without GlyGly (K). The 
relative quantification of proteins (spectral count) was performed using an exponentially 
modified abundance index (emPAI) as described.[10]  
 
TRAFD1 cloning and immunoprecipitation 
A human TRAFD1 ORF clone, IRQMp5018H057D (Source Bioscience), was PCR amplified 
using primers 5’-CAGTGTGGTGGAATTTCGTCCCTGGAAGAGCTAAA-3’ and 5’- 
GATATCTGCAGAATTCTCCTCCTCTTCCTCTTCTGC -3’ and subcloned into a modified pcDNA4 
(Life Technologies, Paisley, UK) vector using In-Fusion (Takara Bio Europe/Clontech, Saint-
Germain-en-Laye,  France) to create a C-terminal FLAG-tag fusion protein. SW1353s were 
transfected using JetPEI (Source Bioscience) and TRAFD1 expression detected by 
immunoblotting. Transfected cells were treated as indicated. Over-expressed TRAFD1 was 
immunoprecipitated from 150 µg of whole-cell-lysate with 1.5 µg of anti-FLAG antibody 
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(Sigma-Aldrich) overnight at 4
o
C, then incubated with 20 µl protein G PLUS-agarose (SCBT) 
for 1 h at 4
o
C. Bound proteins were washed once with lysis buffer and twice with TBS-T and 
eluted with 50 µl 2 x Laemmli sample buffer prior to SDS-PAGE and immunoblotting with the 
anti-FLAG or anti-Ub (after autoclaving of membranes) antibodies. 
 
Real-time reverse transcription-PCR  
Total RNA from cells was extracted using Cells-to-cDNA II kit, RNAse-free DNAse (Life 
Technologies) treated, and cDNA synthesised as described.[11]  Primers and probes were as 
published [7] or designed by the Universal Probe Library (Roche Applied Science, Burgess 
Hill, UK) and were: TRAFD1 F 5’-CAGCCTCAAGAGACCTCACC-3’ and R 5’-
TCCAGGTAACCAGAAGACAGGT-3’ with probe#44; IL6 5’-GATGAGTACAAAAGTCCTGATCCA-3’ 
and R 5’-CTGCAGCCACTGGTTCTGT-3’ with probe#40. Real-time RT-PCR performed and 
analysed as described.[12]  
 
In vitro cartilage degradation assay 
Cultured bovine cartilage discs were incubated with serum-free DMEM containing IL-1 (1 
ng/ml) and Oncostatin M (OSM) (10 ng/ml) ± DMSO/or MG132 (5 µg/ml) and refreshed on 
day 7. Residual cartilage explants were papain digested overnight at 65
o
C. Hydroxyproline 
(OHPro) and glycosaminoglycan (GAG) release were assayed as described.[13]  Conditioned 
media was assessed at day 7 and 14 (presented) for damaged cells using the ToxiLight™ 
BioAssay Kit (Lonza, Slough, UK). Day 0 cartilage was freeze-thawed thrice as a positive 
control of cell damage. 
 
Experimental osteoarthritis 
Experiments were performed on wild-type C57BL/6J or mutant-Ub transgenic mice housed 
in standard cages with ad libitum food and water in accordance with UK Home Office 
regulations.  OA was induced in 8 week old animals, following surgical sectioning of the 
medial meniscotibial ligament with sham operation as control (data not shown).[14] MG132 
or vehicle (50% DMSO/50% polyethylene glycol 300) was delivered via osmotic mini-pump 
(1004; ALZET Osmotic Pumps, Cupertino, CA, USA) implanted subcutaneously and delivering 
0.125 μl/h. Based upon previous studies (e.g. [15]), a single concentration of MG132 (6.6 
Page 7 of 30
http://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Running head: ubiquitination in osteoarthritis 
8 
 
mg/ml) was selected which delivered 1 mg/kg/day (8 mice/group). Osmotic pumps were 
replaced after 4 weeks. 8 weeks post-surgery mice were euthanized and knee joints 
harvested for histological examination and scoring. On average 14 sections/joint, harvested 
at approximately 80 µm intervals, were used for histological scoring by two blinded 
sc rers.[16, 17] Averaged scores for the maximally affected sections are presented. 
Transgenic mutant-Ub animals were as described,[18, 19] where all three transgenic mouse 
lines express human Ub as a linear fusion with a N-terminal 6 x His tag and a C-terminal 
enhanced green fluorescent protein (eGFP), the latter being cleaved to generate eGFP and 
His-tagged Ub.  Since all Ub-transgenes have an N-terminal His-tag none can support linear 
poly-ubiquitination.  K48R Ub and K63R expressing mice also have impaired K48 and K63 
poly-ubiquitination respectively. Genotyping of mice was via GFP visualisation [19] and PCR 
using Ub forward primer: 5’-CATGCAGATCTTCGTGAAGACCCTGACCGGCAAG-3’ and GFP 
reverse primer: 5’ CCTGCCGGTGGTGCAGAT-3’ followed by restriction digestion with the 
endonuclease NgoMIV which only cleaves the K48R PCR amplicon. 
Statistical analysis  
All values are given as mean values of replicates with error bars representing the standard 
error of the mean (SEM). Mann-Whitney U-test was used to assess independent pairs with a 
Student’s t-test used for real-time PCR data analysis using Graphpad Prism Software 
(GraphPad Software, Inc., La Jolla, USA), where * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.  
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RESULTS 
Inhibition of the proteasome reduces cartilage destruction and MMP13 expression 
MG132 reduces the degradation of ubiquitin-conjugated proteins by the 26S proteasome 
complex and because this diverts ubiquitin pools into futile conjugates it has the effect of 
disrupting Ub homeostasis. Since poly-ubiquitination is strongly associated with NF-κB 
signal transduction,[20] we evaluated the effect of MG132 on cytokine-induced cartilage 
destruction using an established bovine cartilage model.[13] MG132 completely 
ameliorated the cartilage damage, as measured using glycosaminoglycan (GAG) and 
hydroxyproline (OHPro) release as surrogates for aggrecan and collagen destruction, 
mediated by the IL-1+OSM combination (Fig. 1A and B). Potential cytotoxicity of the MG132 
treatment was assessed at day 7 and 14 (presented Fig. 1C) and showed low toxicity 
compared to freeze-thawed cartilage or the IL-1+OSM cytokine combination. 
 
Cartilage-collagen turnover is mediated by MMPs, with MMP13 the accepted collagenase in 
OA. In both HAC and SW1353 cells, MG132 completely abolished the IL-1 or poly(I-C) (pIC) 
induced MMP13 expression, the latter stimulus being a double-stranded RNA mimic which is 
a potent inducer of MMP13 in HAC (Fig 1D).[7] Since IL-1 and poly(I-C) activate the NF-κB 
signalling pathway, we examined the effect of MG132 on the activation of this pathway by 
assessing the phosphorylation status of the NF-κB component p65 and the degradation of 
IκBα, which is a consequence of K48 poly-ubiquitination. Interestingly, MG132 caused an 
increase in P-p65 even under basal conditions, as has previously been reported.[21]   Using 
an early time-point of stimulation (15 min), at which IκBα degradation is initiating,[7, 8] we 
observed MG132 caused an increase in higher molecular weight IκBα immune-reactive 
products which we ascribed to be K48 poly-ubquitinated forms (Fig 1E). 
 
Inhibition of the proteasome reduces induced-OA in mice 
Given the ability of MG132 to protect against cytokine-induced cartilage destruction, we 
tested the efficacy of the compound in the murine DMM model of post-traumatic OA.  
MG132 was delivered systemically post-surgery for the eight week duration of the 
experiment at which point OA was assessed by histological scoring.[16]  By this time-point in 
the model, cartilage lesions develop primarily on the central weight-bearing region of the 
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medial-tibial plateau and to a lesser extent the medial-femoral condyles.[14] MG132 
significantly reduced cartilage damage in the most affected medial-tibial plateau but 
showed little evidence of efficacy for the less damaged femoral condyle (Fig. 2A and B). 
Summation of the medial-femoral and tibial histological scores demonstrated an overall 
pr tection of cartilage loss in MG132 administered animals (Fig. 2B). Similarly to other 
studies (e.g. [22]), the administration of MG132 at this dose and for this length of time had 
no effect on the activity/wellbeing of the mice and had no impact on the weight of the 
animals. 
 
K48 poly-ubiquitination plays a role in DMM-induced OA 
To determine the mechanism by which MG132 protected the mice from induced-OA, we 
performed DMM surgery on transgenic mice expressing one of three mutated forms of Ub, 
unable to form specific poly-Ub chains, in addition to their endogenous Ub genes.[18] When 
examining the medial tibial plateau none of the mutant-Ub mice were protected from OA 
with in fact a significant enhancement of the OA score of the K63R mice (Fig. 3A and B). 
However, the medial femoral condyles of the K48R mice showed a significant reduction in 
the OA score compared to either ‘wild-type’ animals or ‘wild-type’ Ub transgenic animals 
(Fig. 3A and B). Overall summation of the histological scores from both medial plateaus 
revealed no significant differences between transgenic and ‘wild-type’ animals (Fig. 3B). 
 
TRAFD1 positively regulates induced MMP13 expression 
Many components of signalling pathways are known to be modulated by Ub conjugation. 
Therefore we attempted to identify novel proteins ubiquitinated under either basal or 
stimulated conditions which may be important OA given our mouse-model findings, using 
chondrosarcoma SW1353 cell extracts. Ubiquitinated proteins were first enriched using 
TUBEs which have a nanomolar binding affinity for poly-ubiquitinated proteins.[9] After 
confirmation of the enrichment of Ub conjugated proteins (Fig. 4A, mid-panel), proteins 
were identified by MS using spectral counts to quantify relative abundance. We identified 
176 proteins in total and the protein with the highest emPAI (exponentially modified protein 
abundance index) was ubiquitin in all samples (Supplementary table). Identified proteins 
with a reported role in NF-κB signalling are listed (Table 1). Of these, TRAFD1 was identified 
only under basal conditions and has been identified as a negative regulator of cytokine 
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signalling.[23]  We therefore confirmed the association of TRAFD1 with ubiquitin by over-
expression and immunoprecipitation of the protein followed by immunoblotting with anti-
Ub antibody (Fig. 4B). Using RNAi we specifically depleted TRAFD1 from SW1353 cells (Fig. 
4C) and measured IL-1- or poly(I-C)-induced gene expression. Depletion of TRAFD1 reduced 
both basal and induced expression of MMP13 (Fig. 4D). Previous work with TRAFD1 had 
focussed on IL6 regulation, again similar to our findings with MMP13, we observed a 
reduction in induced IL6 expression following TRAFD1 depletion (Fig. 4E). 
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DISCUSSION 
To our knowledge this is the first detailed study to evaluate the therapeutic potential of 
inhibition of the UPS system for OA. 
MG132 is a peptide aldehyde which directly inhibits the active site within the 20S core 
particle, the catalytic sub-complex of the 26S proteasome. Using the DMM OA model we 
observed that 8-weeks post surgery, MG132-administered mice had a significant protection 
against OA-like cartilage erosions.  Similarly, using a well established bovine ex vivo model of 
cartilage destruction, mediated by pro-inflammatory cytokines,[13] MG132 totally blocked 
resorption.  Proteasomal inhibitors are considered as potential remedies for autoimmune 
and inflammatory diseases, including rheumatoid arthritis (RA) and have shown efficacy in 
animal models, including in rat models of OA.[15, 24, 25] This is principally via their ability to 
inhibit NF-κB activation.[5] Thus, it was perhaps not surprising that here MG132 prevented 
cartilage destruction in our explant model, presumably via limiting IκBα degradation, NF-κB 
signal transduction and MMP13 expression, all of which we demonstrated in vitro. 
The NF-κB pathway inhibitor IκB was the first identified substrate of the UPS,[26] where 
following its K48 poly-ubiquitination it is degraded by the proteasome.  In fact, multiple 
different Ub-conjugated proteins are involved in NF-κB signalling. For example, linear poly-
ubiquitination of NEMO, K63 poly-ubiquitination of TRAF6 (itself the responsible E3 ligase), 
and K11 poly-ubiquitination of RIP1, all regulate the NF-κB pathway.[20] Similarly, 
deubiquitination plays an important role in NF-κB signalling, exemplified by A20.[27]  
Although MG132 is a proteasome inhibitor it disrupts the entire UPS, leading to an 
accumulation of K48 poly-ubiquitination protein and a lack of bioavailable mono-Ub. In an 
attempt to resolve the mode of action of MG132 in the protection of DMM-induced OA we 
used ‘wild-type’, K48R and K63R Ub transgenic mice in further DMM studies.  We observed 
that the K63R mice developed modestly, but significantly, worse OA. K63 poly-Ub chains are 
involved in range of cellular processes including intracellular trafficking and autophagy 
where their formation causes proteins to accumulate to the aggresome.[28] Autophagy is 
protective for healthy cartilage, where loss of the process is associated with cell death and 
OA-onset.[29] We therefore speculate that the K63R mice would have reduced autophagy, 
explaining the observed increase in OA score. Our data also indicates that linear poly-
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ubiquitination has little importance in DMM-induced OA since all three transgenic Ub mice 
are incapable of this form of conjugation with their respective Ub-transgene. Somewhat 
pheno-copying the MG132 data, K48R transgenic animals showed significant protection 
from DMM-OA, but only on the less affected medial-femoral condyle, suggestive of a delay 
in OA-onset. These data warrant further investigation into the role of K48 poly-
ubiquitination at earlier time points during DMM where lesions on the tibial plateau are 
initiating.  A limitation of these studies is that all the transgenic mice are still able to make 
all poly-Ub conjugates because they still express the four copies of the endogenous Ub 
genes, UBA52, RPS27A, UBB  and UBC,[30] although data suggest the transgenic mutant Ub 
acts as a dominant negative form.[18] A further limitation is that the transgenic animals 
were maintained on FVB/N genetic background, rather than C57Bl/6, although we still 
observed reduced OA in K48R mice compared to the WT-Ub transgenics or ‘WT’ C57Bl/6 
mice, which themselves developed OA indistinguishable from each other (Fig 3). 
Given the protection mediated by both MG132 and the K48R Ub transgene the data indicate 
a role for the 26S proteasome and potentially NF-κB signalling in DMM-OA. NF-κB signalling 
is the major inflammatory pathway but has yet to be investigated in DMM-induced OA, 
although the pathway has been extensively studied in chondrocytes and its inhibition can 
suppress OA in an experimental model.[31] In fact the role of inflammation, and in 
particular IL-1, in OA remains controversial.[32]  Importantly, although we used pro-
inflammatory cytokines to study NF-κB activation and MMP13 expression, inflammatory 
signalling pathways, including NF-κB, can be activated by other signals including mechano-
transduction.[33] Chondrocytes are well known to respond to biomechanical signals to 
maintain cartilage homeostasis. The magnitude of these signals are critical for the control of 
the activation or inhibition of pro-inflammatory genes, even in the absence of classical 
inflammatory stimuli.  Further, DMM-induced OA is mechanosensitive with several pro-
inflammatory genes that activate NF-κB, including IL1b and IL6, induced early following 
surgery and suppressed by joint immobilisation [34] - adding validity to our use of cytokines 
in vitro and our emphasis on NF-κB signalling.  However, a number of other signalling 
pathways important for cartilage development and integrity are regulated by the UPS 
including TGF-β and Wnt signalling.[35, 36] Our data cannot preclude that MG132 or the 
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K48R Ub-transgene may be affecting these or other pathways to reduce the cartilage 
damage induced following DMM surgery.  
Given that multiple signalling pathways converge on the upregulation of aggrecanases and 
collagenases, especially MMP13, we sought to identify potentially novel Ub involved in such 
pathways using a novel proteomic method.  From these proteomic data we identified 
TRAFD1, although we were unable to verify that the protein was directly ubiquitinated since 
the identified peptide lacked a characteristic lysine-diglycine modification found after 
trypsin digestion of ubiquitinated peptides. However, TRAFD1 has been previously identified 
as being ubiquitinated in large-scale proteomic screens for Ub-modified proteins,[37-39] 
with K103, K129 and K485 of the human protein showing modification. Here, we 
overexpressed and immunoprecipitated a tagged version of TRADF1 and confirmed the co-
immunoprecipitation of Ub, presumably conjugated to TRAFD1.  
We chose TRAFD1, also known as FLN29, for further study based upon previous work linking 
the protein to toll-like receptor (TLR) and retinoic acid-inducible gene 1 (RIG-1)-like helicase 
(RLH) signalling,[23, 40] and thus NF-κB signalling.  In these studies, contrary to our findings, 
TRAFD1 is reportedly a negative regulator of TLR and RLH signalling.[23]  The discrepancies 
between our findings and those published could perhaps be explained by differences in the 
cells or species used but clearly warrant further investigation.  TRAFD1 was also reportedly 
important for IRF-3 dimerisation,[23] a process important for poly(I-C)-induced MMP13 
expression by chondrocytes.[8]  
Finally, Ub is a member of a family of ubiquitin-like proteins which includes the Small 
Ubiquitin-related Modifiers (SUMO). SUMO has recently been linked to MMP13 expression 
and potentially RA.[41] Thus, further work into the role of ubiquitin-like proteins in the 
arthritides is required. 
In summary, here we describe for the first time that disruption of the UPS system is able to 
partially protect from OA-like cartilage destruction in the DMM murine model. Using a 
proteomic screen we identified TRAFD1 as a potential novel Ub target in chondrocytes and 
demonstrate that the depletion of the gene reduces the inflammatory induction of the 
potent collagenase MMP13.  Further work is required to determine whether the protection 
from OA observed here by inhibition of the UPS is via TRAFD1, inhibition of NF-κB signalling, 
or perhaps via modulation of other pathways such as Wnt or TGF-β signalling.  
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Table 1. TUBE-enriched, Ub-associated protein with a role in NF-κB signalling 
 
Protein 
# 
protein 
accession short name protein description  
emPAI 
uniprot 
accession 
 
      unst IL-1 pIC   
1 IPI00100154 TOLLIP   Toll-interacting protein 0.1 0.1 0.1 Q9H0E2 
2 IPI00009146 TRAFD1   TRAF-type zinc finger domain-containing protein 1 0.05  -----  ----- O14545 
3 IPI00094740 RNF31  Isoform 1 of RING finger protein 31  ----- 0.05  ----- Q96EP0 
4 IPI00000816 YWHAE  Isoform 1 of 14-3-3 protein epsilon  ----- 0.23 0.11 P62258 
5 IPI00021263 YWHAZ   14-3-3 protein zeta/delta 0.38  -----  ----- P63104 
6 IPI00220740 NPM1   Isoform 2 of Nucleophosmin  -----  ----- 0.5 P06748 
7 IPI00179473 SQSTM1   Isoform 1 of Sequestosome-1 0.65 0.65 0.29 Q13501 
8 IPI00299147 SUMO3   Small ubiquitin-related modifier 3 1.1 0.64 0.64 P55854 
 
* emPAI, Exponentially modified protein abundance index.[10] 
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Figure legends 
Figure 1.  UPS inhibition prevents cartilage destruction via blockade of NF-κB signaling to 
MMP13. (A) and (B). Bovine nasal cartilage was cultured in serum-free medium in the 
presence of either medium, or medium plus IL-1 and OSM both ± MG132 or DMSO vehicle 
as described for 14 days. (A) Glycosaminoglycan (GAG) release into the medium was assayed 
using the dimethylmethylene blue assay [13] and is shown for day 7. (B). The levels of 
collagen fragments released into the medium were determined by measurement of 
hydroxyproline (OHPro).[13] Results shown are for the cumulative collagen release at day 14 
of culture and expressed as a percentage of the total (mean ± SD). Experiments were 
performed with three bovine noses with each experiment performed in quadruplicate. (C). 
Treatment toxicity was measured in condition medium (day 7 and 14 - presented) using the 
ToxiLight™ BioAssay Kit. Data is average (n=4) emitted light from a single bovine cartilage 
experiment with freeze-thawed cartilage used as a positive control and set to 100% toxicity. 
(D). SW1353 cells or HAC were stimulated with ligands (pIC = poly(I-C)) ± MG132 or DMSO 
vehicle, as described and labelled, for 6 h or 24 h respectively. MMP13 and 18S expression 
were measured using real-time RT-PCR.  (E). SW1353 cell were stimulated as described for 
15 min and isolated protein subjected to immunoblotting with the indicated antibodies. 
GAPDH was used as a loading control. Real-time PCR results are combined data from 3 
separate experiments (n=4/experiment) or representative of two patient HAC. 
Immunoblotting is representative of two experiments. 
 
Figure 2. MG132 reduces cartilage destruction in the ‘destabilisation of the medial 
meniscus’ model in vivo.  (A). OA in C57BL/6J mice was induced following surgical 
destabilization of the medial meniscus (DMM) as described. MG132 (1 mg/kg/day) or 
vehicle (DMSO/PEG) were delivered via subcutaneously implanted osmotic pump, with 
pumps replacement after 4 weeks. Data are shown at 8 weeks. Frontal sections (5 μm) were 
stained with haematoxylin, safranin-O/fast green.  Sections shown are representative of the 
most affected from a selected mouse (DMSO vehicle or MG132) and show the medial 
compartment of the knee joint (5 x magnification). (B). Approximately fourteen sections 
from each mouse were graded by two blinded scorers using a validated scoring system.[16] 
The means of the highest score for each animal are plotted (n=8 per group) for the medial 
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femoral condyle and tibial plateau and summation of both, with closed circles and open 
squares for vehicle or MG312 treated animals respectively. Line represents mean and error 
bars are SEM.  Statistical significance was calculated using a Mann Whitney U test. 
 
Figure 3.  Transgenic mutated ubiquitins differentially affect DMM-induced OA. (A). OA 
was induced in 10-week old mice transgenic for wild-type ubiquitin, K48R or K63R mutant 
ubiquitin on the FVB/N genetic background.  After 8 weeks animals were sacrificed and knee 
frontal sections (5 μm) stained with haematoxylin, safranin-O/fast green.  Sections shown 
are representative of the most affected from a selected mouse for each genotype and show 
the medial compartment of the knee joint (5 x magnification). (B). Approximately fourteen 
sections from each mouse were graded by two blinded scorers using a validated scoring 
system.[16] The means of the highest score for each animal are plotted for the medial 
femoral condyle and tibial plateau and summation of both. C57BL/6J mice (n=22) from 
parallel surgery, by the same surgeon, were used to determine the effect transgenic ‘wild-
type’ Ub. Line represents mean and error bars are SEM.  Statistical significance was 
calculated using a Mann Whitney U test. 
 
Figure 4. TRAFD1 is a novel ubiquitinated substrate involved in inflammatory signalling. 
(A). Protein extracts from SW1353 cells were enriched for poly-ubiqtuinated substrates 
using TUBEs as described, with colloidal coomassie staining (upper-panel) and 
immunoblotting with an anti-Ub (Ub; mid-panel) antibody used to verify enrichment.  
Enriched ubiquitin-conjugated proteins were subjected to MS. n-b is ‘non-bound’ protein 
collected after incubation with the TUBEs (B). SW1353 cells were transfected with a 
TRAFD1-FLAG construct or empty vector and overexpression confirmed by immunoblotting. 
Transfected cells were stimulated as indicated and FLAG-tagged proteins enriched by FLAG-
immunoprecipitation, which was confirmed by FLAG-immunoblotting.  (C). SW1353 cells 
were transfected with the indicated siRNA and TRAFD1 depletion confirmed by real-time RT-
PCR.  (D) and (E) SW1353 cells were transfected with the indicated siRNA, stimulated with 
IL-1 (solid bars) or poly(I-C)(pIC) (shaded bars) as indicated for 6 or 24 h, and MMP13 (D) or 
IL6 (E) expression measured by real-time RT-PCR. Data are shown as fold change relative to 
the cells transfected with a non-targeting siRNA (siCon).  Real-time PCR data are from 3 
separate experiments performed in quadruplicate. 
Page 23 of 30
http://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
  
 
 
Figure 1.  UPS inhibition prevents cartilage destruction via blockade of NF-κB signaling to MMP13. (A) and 
(B). Bovine nasal cartilage was cultured in serum-free medium in the presence of either medium, or medium 
plus IL-1 and OSM both ± MG132 or DMSO vehicle as described for 14 days. (A) Glycosaminoglycan (GAG) 
release into the medium was assayed using the dimethylmethylene blue assay [13] and is shown for day 7. 
(B). The levels of collagen fragments released into the medium were determined by measurement of 
hydroxyproline (OHPro).[13] Results shown are for the cumulative collagen release at day 14 of culture and 
expressed as a percentage of the total (mean ± SD). Experiments were performed with three bovine noses 
with each experiment performed in quadruplicate. (C). Treatment toxicity was measured in condition 
medium (day 7 and 14 - presented) using the ToxiLight™ BioAssay Kit. Data is average (n=4) emitted light 
from a single bovine cartilage experiment with freeze-thawed cartilage used as a positive control and set to 
100% toxicity. (D). SW1353 cells or HAC were stimulated with ligands (pIC = poly(I-C)) ± MG132 or DMSO 
vehicle, as described and labelled, for 6 h or 24 h respectively. MMP13 and 18S expression were measured 
using real-time RT-PCR.  (E). SW1353 cell were stimulated as described for 15 min and isolated protein 
subjected to immunoblotting with the indicated antibodies. GAPDH was used as a loading control. Real-time 
PCR results are combined data from 3 separate experiments (n=4/experiment) or representative of two 
patient HAC. Immunoblotting is representative of two experiments.  
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Figure 2. MG132 reduces cartilage destruction in the ‘destabilisation of the medial meniscus’ model in 
vivo.  (A). OA in C57BL/6J mice was induced following surgical destabilization of the medial meniscus (DMM) 
as described. MG132 (1 mg/kg/day) or vehicle (DMSO/PEG) were delivered via subcutaneously implanted 
osmotic pump, with pumps replacement after 4 weeks. Data are shown at 8 weeks. Frontal sections (5 µm) 
were stained with haematoxylin, safranin-O/fast green.  Sections shown are representative of the most 
affected from a selected mouse (DMSO vehicle or MG132) and show the medial compartment of the knee 
joint (5 x magnification). (B). Approximately fourteen sections from each mouse were graded by two blinded 
scorers using a validated scoring system.[16] The means of the highest score for each animal are plotted 
(n=8 per group) for the medial femoral condyle and tibial plateau and summation of both, with closed circles 
and open squares for vehicle or MG312 treated animals respectively. Line represents mean and error bars 
are SEM.  Statistical significance was calculated using a Mann Whitney U test.  
101x65mm (300 x 300 DPI)  
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Figure 3.  Transgenic mutated ubiquitins differentially affect DMM-induced OA. (A). OA was induced in 10-
week old mice transgenic for wild-type ubiquitin, K48R or K63R mutant ubiquitin on the FVB/N genetic 
background.  After 8 weeks animals were sacrificed and knee frontal sections (5 µm) stained with 
haematoxylin, safranin-O/fast green.  Sections shown are representative of the most affected from a 
selected mouse for each genotype and show the medial compartment of the knee joint (5 x magnification). 
(B). Approximately fourteen sections from each mouse were graded by two blinded scorers using a validated 
scoring system.[16] The means of the highest score for each animal are plotted for the medial femoral 
condyle and tibial plateau and summation of both. C57BL/6J mice (n=22) from parallel surgery, by the same 
surgeon, were used to determine the effect transgenic ‘wild-type’ Ub. Line represents mean and error bars 
are SEM.  Statistical significance was calculated using a Mann Whitney U test.  
166x158mm (300 x 300 DPI)  
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Figure 4. TRAFD1 is a novel ubiquitinated substrate involved in inflammatory signalling. (A). Protein extracts 
from SW1353 cells were enriched for poly-ubiqtuinated substrates using TUBEs as described, with colloidal 
coomassie staining (upper-panel) and immunoblotting with an anti-Ub (Ub; mid-panel) antibody used to 
verify enrichment.  Enriched ubiquitin-conjugated proteins were subjected to MS. n-b is ‘non-bound’ protein 
collected after incubation with the TUBEs (B). SW1353 cells were transfected with a TRAFD1-FLAG construct 
or empty vector and overexpression confirmed by immunoblotting. Transfected cells were stimulated as 
indicated and FLAG-tagged proteins enriched by FLAG-immunoprecipitation, which was confirmed by FLAG-
immunoblotting.  (C). SW1353 cells were transfected with the indicated siRNA and TRAFD1 depletion 
confirmed by real-time RT-PCR.  (D) and (E) SW1353 cells were transfected with the indicated siRNA, 
stimulated with IL-1 (solid bars) or poly(I-C)(pIC) (shaded bars) as indicated for 6 or 24 h, and MMP13 (D) 
or IL6 (E) expression measured by real-time RT-PCR. Data are shown as fold change relative to the cells 
transfected with a non-targeting siRNA (siCon).  Real-time PCR data are from 3 separate experiments 
performed in quadruplicate.  
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Protein # prot_acc short name prot_desc emPAI emPAI emPAI prot_mass prot_score prot_score prot_score prot_matches_sign prot_matches_sign prot_matches_sign uniprot_acc uniprot_name
unst IL-1 pIC unst IL-1 pIC unst IL-1 pIC
1 IPI00000811 PSMB6  Proteasome subunit beta type-6 0.8 1.02 1.02 25570 186 232 245 5 6 6 P28072 Proteasome subunit beta type-6
2 IPI00001639 KPNB1  Importin subunit beta-1 0.03 0.03 0.03 98420 66 71 81 1 1 1 Q14974 Importin subunit beta-1
3 IPI00001676 NPLOC4  Isoform 2 of Nuclear protein localization protein 4 homolog 0.19 0.42 0.19 70215 207 290 209 4 8 4 Q8TAT6 Nuclear protein localization protein 4 homolog
4 IPI00002134 PSMD5  26S proteasome non-ATPase regulatory subunit 5 0.06 0.06 0.06 56560 52 63 46 1 1 1 Q16401 26S proteasome non-ATPase regulatory subunit 5
5 IPI00003217 PSMB7 Proteasome subunit beta type-7 1.45 2.64 1.99 30288 378 616 470 9 13 11 Q99436 Proteasome subunit beta type-7
6 IPI00003362 HSPA5  78 kDa glucose-regulated protein 0.53 0.46 0.34 72402 312 444 330 10 9 6 P11021 78 kDa glucose-regulated protein
7 IPI00003442 HIF1A  Isoform 1 of Hypoxia-inducible factor 1-alpha 0.3 0.3 0.26 93467 285 307 259 8 8 7 Q16665 Hypoxia-inducible factor 1-alpha
8 IPI00003865 HSPA8  Isoform 1 of Heat shock cognate 71 kDa protein 2.49 2.49 2.64 71082 1206 1077 1213 30 29 30 P11142 Heat shock cognate 71 kDa protein
9 IPI00006395 GNAL  Guanine nucleotide-binding protein G(olf) subunit alpha 0.07 0.07 0.07 44794 42 50 46 1 1 1 P38405 Guanine nucleotide-binding protein G(olf) subunit alpha
10 IPI00007611 ATP5O  ATP synthase subunit O, mitochondrial 0.89 1.15 0.89 23377 241 257 177 6 7 5 P48047 ATP synthase subunit O, mitochondrial
11 IPI00007752 TUBB2C  Tubulin beta-2C chain 2.57 3.55 3.03 50255 870 995 971 25 27 25 P68371 Tubulin beta-4B chain
12 IPI00008219 RAD23A  UV excision repair protein RAD23 homolog A 0.17 0.17 0.17 39642 67 89 94 2 3 3 P54725 UV excision repair protein RAD23 homolog A
13 IPI00008433 RPS5  40S ribosomal protein S5 1.17 0.3 1.17 23033 290 101 283 6 2 6 P46782 40S ribosomal protein S5
14 IPI00008438 RPS10  40S ribosomal protein S10 0.6 0.17 0.37 18886 153 64 134 4 1 3 P46783 40S ribosomal protein S10
15 IPI00011126 PSMC1   26S protease regulatory subunit 4 2.04 2.24 2.66 49325 770 752 842 20 21 22 P62191 26S protease regulatory subunit 4
16 IPI00011253 RPS3   40S ribosomal protein S3 3.79 2.42 3.28 26842 386 366 410 14 10 12 P23396 40S ribosomal protein S3
17 IPI00011603 PSMD3  26S proteasome non-ATPase regulatory subunit 3 1.23 1.23 1.59 61054 572 532 642 16 16 19 O43242 26S proteasome non-ATPase regulatory subunit 3
18 IPI00011609 UBE3A  Isoform II of Ubiquitin-protein ligase E3A 0.13 0.03 0.06 101593 98 66 97 4 1 2 Q05086 Ubiquitin-protein ligase E3A
19 IPI00012011 CFL1  Cofilin-1 0.61 0.61 0.61 18719 191 200 176 3 3 3 P23528 Cofilin-1
20 IPI00012268 PSMD2   26S proteasome non-ATPase regulatory subunit 2 2.08 2.28 2.18 100877 1381 1580 1468 39 40 37 Q13200 26S proteasome non-ATPase regulatory subunit 2
21 IPI00013296 RPS18;RPS18P9  40S ribosomal protein S18 2.79 2.79 3.48 17708 280 277 295 7 9 9 P62269 40S ribosomal protein S18
22 IPI00014151 PSMD6  26S proteasome non-ATPase regulatory subunit 6 2.54 2.1 2.78 45787 593 602 774 20 17 20 Q15008 26S proteasome non-ATPase regulatory subunit 6
23 IPI00016832 PSMA1   Isoform Short of Proteasome subunit alpha type-1 5.8 4.03 3.54 29822 503 398 449 19 17 14 P25786 Proteasome subunit alpha type-1
24 IPI00018398 PSMC3   26S protease regulatory subunit 6A 5.33 3.12 4.6 49458 1075 820 942 30 23 30 P17980 26S protease regulatory subunit 6A
25 IPI00019927 PSMD7   26S proteasome non-ATPase regulatory subunit 7 1.09 1.09 0.77 37060 358 333 273 9 9 7 P51665 26S proteasome non-ATPase regulatory subunit 7
26 IPI00020042 PSMC4  Isoform 1 of 26S protease regulatory subunit 6B 3.67 4.31 3.67 47451 906 1033 979 25 27 25 P43686 26S protease regulatory subunit 6B
27 IPI00021290 ACLY  ATP-citrate synthase 0.03 0.03 0.03 121674 73 64 42 1 1 1 P53396 ATP-citrate synthase
28 IPI00021435 PSMC2  26S protease regulatory subunit 7 3.45 3.18 5.07 49002 1007 965 957 28 26 31 P35998 26S protease regulatory subunit 7
29 IPI00021439 ACTB   Actin, cytoplasmic 1 4.26 4.26 6.55 42052 1014 883 1400 25 22 30 P60709 Actin, cytoplasmic 1
30 IPI00021440 ACTG1  Actin, cytoplasmic 2 3.89 4.26 7.11 42108 1051 892 1400 24 22 30 P63261 Actin, cytoplasmic 2
31 IPI00022202 SLC25A3   Isoform A of Phosphate carrier protein, mitochondrial 0.16 0.16 0.08 40525 69 84 51 2 2 1 Q00325 Phosphate carrier protein, mitochondrial
32 IPI00022298 CHRNA1  Isoform 2 of Acetylcholine receptor subunit alpha 0.06 0.06 0.06 54966 44 47 45 1 1 1 P02708 Acetylcholine receptor subunit alpha
33 IPI00022694 PSMD4  Isoform Rpn10A of 26S proteasome non-ATPase regulatory subunit 4 1.26 1.82 1.43 40939 424 590 455 11 13 12 P55036 26S proteasome non-ATPase regulatory subunit 4
34 IPI00022774 VCP Transitional endoplasmic reticulum ATPase 4.51 3.34 3.34 89950 2324 2096 2200 54 47 50 P55072 Transitional endoplasmic reticulum ATPase
35 IPI00023191 TOM1   cDNA FLJ54710, highly similar to Target of Myb protein 1 0.32 0.25 0.25 55083 287 227 184 6 4 4 B4DKQ5 cDNA FLJ54710, highly similar to Target of Myb protein 1
36 IPI00023919 PSMC5   26S protease regulatory subunit 8 4.64 3.93 4.27 45768 1124 1005 1144 28 24 27 P62195 26S protease regulatory subunit 8
37 IPI00024067 CLTC  Isoform 1 of Clathrin heavy chain 1 0.19 0.31 0.19 193260 367 598 474 11 16 11 Q00610 Clathrin heavy chain 1
38 IPI00024175 PSMA7 Isoform 1 of Proteasome subunit alpha type-7 2.62 1.92 2.25 28041 527 487 437 12 10 11 O14818 Proteasome subunit alpha type-7
39 IPI00024821 PSMD14  26S proteasome non-ATPase regulatory subunit 14 1.01 0.84 0.55 34726 283 211 199 9 7 5 O00487 26S proteasome non-ATPase regulatory subunit 14
40 IPI00025019 PSMB1  Proteasome subunit beta type-1 6.55 2.07 2.44 26700 616 487 555 17 10 11 P20618 Proteasome subunit beta type-1
41 IPI00026781 FASN  Fatty acid synthase 0.01 0.03 0.02 275877 86 146 117 1 3 2 P49327 Fatty acid synthase
42 IPI00028004 PSMB3  Proteasome subunit beta type-3 1.8 2.19 2.19 23219 456 431 430 9 9 9 P49720 Proteasome subunit beta type-3
43 IPI00028006 PSMB2  Proteasome subunit beta type-2 1.49 1.18 1.49 22993 318 301 353 8 6 7 P49721 Proteasome subunit beta type-2
44 IPI00029623 PSMA6  Proteasome subunit alpha type-6 2.65 3.53 3.07 27838 425 529 480 12 13 13 P60900 Proteasome subunit alpha type-6
45 IPI00032957 UBE2I  SUMO-conjugating enzyme UBC9 0.18 0.38 0.18 18223 64 104 80 1 2 1 P63279 SUMO-conjugating enzyme UBC9
46 IPI00033030 ADRM1  Proteasomal ubiquitin receptor ADRM1 0.24 0.33 0.15 42412 116 173 114 3 4 2 Q16186 Proteasomal ubiquitin receptor ADRM1
47 IPI00100154 TOLLIP  Toll-interacting protein 0.1 0.1 0.1 30490 56 53 52 1 1 1 Q9H0E2 Toll-interacting protein
48 IPI00105598 PSMD11  Proteasome 26S non-ATPase subunit 11 variant (Fragment) 3.32 2.35 2.57 47790 858 737 725 24 20 22 O00231 26S proteasome non-ATPase regulatory subunit 11
49 IPI00157790 KIAA0368  proteasome-associated protein ECM29 homolog 0.01 0.01 0.03 225491 58 59 85 1 1 2 Q5VYK3 Proteasome-associated protein ECM29 homolog
50 IPI00171199 PSMA3  Isoform 2 of Proteasome subunit alpha type-3 1.94 1.64 1.64 27858 339 297 293 10 9 9 P25788 Proteasome subunit alpha type-3
51 IPI00179298 HUWE1  Uncharacterized protein 0.07 0.08 0.05 485780 316 472 287 10 12 7 Q7Z6Z7 E3 ubiquitin-protein ligase HUWE1
52 IPI00179330 RPS27A  Ubiquitin-40S ribosomal protein S27a 286.43 465.95 336.9 18296 4986 5380 5210 165 173 165 P62979 Ubiquitin-40S ribosomal protein S27a
53 IPI00179473 SQSTM1  Isoform 1 of Sequestosome-1 0.65 0.65 0.29 48455 427 396 231 8 8 4 Q13501 Sequestosome-1
54 IPI00180675 TUBA1A  Tubulin alpha-1A chain 3.47 2.97 2.74 50788 1012 962 914 27 23 24 Q71U36 Tubulin alpha-1A chain
55 IPI00185374 PSMD12  26S proteasome non-ATPase regulatory subunit 12 3.43 2.52 3.43 53270 1049 771 1102 26 22 27 O00232 26S proteasome non-ATPase regulatory subunit 12
56 IPI00186290 EEF2   Elongation factor 2 0.1 0.17 0.07 96246 108 163 80 3 5 2 P13639 Elongation factor 2
57 IPI00215780 RPS19 40S ribosomal protein S19 1.5 1.5 2 16051 170 178 163 5 5 6 P39019 40S ribosomal protein S19
58 IPI00216049 HNRNPK  Isoform 1 of Heterogeneous nuclear ribonucleoprotein K 0.06 0.06 0.06 51230 52 50 59 1 1 1 P61978 Heterogeneous nuclear ribonucleoprotein K
59 IPI00217966 LDHA Isoform 1 of L-lactate dehydrogenase A chain 0.39 0.39 0.28 36950 165 210 112 4 4 3 P00338 L-lactate dehydrogenase A chain
60 IPI00218292 UFD1L  Isoform Short of Ubiquitin fusion degradation protein 1 homolog 0.19 0.09 0.42 34763 66 53 128 2 1 4 Q92890 Ubiquitin fusion degradation protein 1 homolog
61 IPI00219018 GAPDH  Glyceraldehyde-3-phosphate dehydrogenase 0.4 0.65 0.4 36201 235 309 223 4 7 4 P04406 Glyceraldehyde-3-phosphate dehydrogenase
62 IPI00219622 PSMA2 Proteasome subunit alpha type-2 4.04 3.49 4.04 25996 621 566 630 15 13 15 P25787 Proteasome subunit alpha type-2
63 IPI00220102 DNAJB2   Isoform 3 of DnaJ homolog subfamily B member 2 0.19 0.53 0.4 35672 99 160 144 2 5 4 P25686 DnaJ homolog subfamily B member 2
64 IPI00291922 PSMA5  Proteasome subunit alpha type-5 3.36 2.89 3.36 26565 652 495 675 14 13 15 P28066 Proteasome subunit alpha type-5
65 IPI00299147 SUMO3  Small ubiquitin-related modifier 3 1.1 0.64 0.64 11687 122 133 111 4 4 3 P55854 Small ubiquitin-related modifier 3
66 IPI00299155 PSMA4  Proteasome subunit alpha type-4 3.57 5.19 4.05 29750 751 784 773 16 18 17 P25789 Proteasome subunit alpha type-4
67 IPI00299468 SCD  Acyl-CoA desaturase 0.08 0.08 0.08 41667 56 84 60 1 1 1 O00767 Acyl-CoA desaturase
68 IPI00375380 PSMD13  Isoform 2 of 26S proteasome non-ATPase regulatory subunit 13 1.87 2.3 3.07 43257 518 558 716 15 17 20 Q9UNM6 26S proteasome non-ATPase regulatory subunit 13
69 IPI00396485 EEF1A1  Elongation factor 1-alpha 1 0.62 0.94 0.72 50451 289 438 290 8 11 9 P68104 Elongation factor 1-alpha 1
70 IPI00414676 HSP90AB1  Heat shock protein HSP 90-beta 0.2 0.25 0.25 83554 203 210 185 5 6 5 P08238 Heat shock protein HSP 90-beta
71 IPI00418169 ANXA2 Isoform 2 of Annexin A2 0.45 0.57 0.45 40671 180 213 172 5 6 5 P07355 Annexin A2
72 IPI00419575 GET4  Uncharacterised protein family UPF0363 protein 0.09 0.18 0.18 36808 99 112 127 1 2 2 Q7L5D6 Golgi to ER traffic protein 4 homolog
73 IPI00440493 ATP5A1  ATP synthase subunit alpha, mitochondrial 0.05 0.11 0.17 59828 42 68 92 1 2 3 P25705 ATP synthase subunit alpha, mitochondrial
74 IPI00465128 BAG6   Isoform 1 of Large proline-rich protein BAG6 0.51 0.59 0.51 119790 540 662 552 16 18 16 P46379 Large proline-rich protein BAG6
75 IPI00465248 ENO1  Isoform alpha-enolase of Alpha-enolase 0.29 0.67 0.47 47481 193 469 275 4 8 6 P06733 Alpha-enolase
76 IPI00465439 ALDOA  Fructose-bisphosphate aldolase A 0.16 0.26 0.16 39851 82 100 85 2 3 2 P04075 Fructose-bisphosphate aldolase A
77 IPI00479186 PKM2  Isoform M2 of Pyruvate kinase isozymes M1/M2 0.69 0.78 0.78 58470 401 402 371 10 11 11 P14618 Pyruvate kinase isozymes M1/M2
78 IPI00479306 PSMB5   Isoform 1 of Proteasome subunit beta type-5 2.53 4.37 2.92 28633 536 702 615 12 16 13 P28074 Proteasome subunit beta type-5
79 IPI00479722 PSME1  Proteasome activator complex subunit 1 0.68 0.37 0.87 28876 191 114 213 5 3 5 Q06323 Proteasome activator complex subunit 1
80 IPI00555956 PSMB4  Proteasome subunit beta type-4 2.82 2.82 3.24 29242 661 700 801 13 13 14 P28070 Proteasome subunit beta type-4
81 IPI00784154 HSPD1  60 kDa heat shock protein, mitochondrial 0.11 0.11 0.16 61187 92 75 108 2 2 3 P10809 60 kDa heat shock protein, mitochondrial
82 IPI00926977 PSMC6  26S protease regulatory subunit 10B 3 1.88 2.07 46053 726 566 551 22 16 17 P62333 26S protease regulatory subunit 10B
83 IPI00930688 TUBA1B Tubulin alpha-1B chain 4.04 3.75 3.47 50804 1198 1043 983 30 26 27 P68363 Tubulin alpha-1B chain
84 IPI00937278 PSMD8  26S proteasome non-ATPase regulatory subunit 8 0.58 0.26 0.58 39872 185 147 227 6 3 6 P48556 26S proteasome non-ATPase regulatory subunit 8
85 IPI00943181 PSME2  Uncharacterized protein 1.28 0.85 1.05 29279 342 328 338 8 5 7 Q9UL46 Proteasome activator complex subunit 2
Identified in all samples 
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86 IPI00982304 PSMC3  Uncharacterized protein 3.5 2.73 5.55 15631 272 298 347 9 8 11 E9PLQ8 26S protease regulatory subunit 6A
87 IPI00000816 YWHAE  Isoform 1 of 14-3-3 protein epsilon  ----- 0.23 0.11 29326  ----- 70 65  ----- 2 1 P62258 14-3-3 protein epsilon
88 IPI00007188 SLC25A5  ADP/ATP translocase 2  ----- 0.1 0.1 33059  ----- 49 73  ----- 1 1 P05141 ADP/ATP translocase 2
89 IPI00007765 HSPA9   Stress-70 protein, mitochondrial  ----- 0.09 0.13 73920  ----- 75 71  ----- 2 2 P38646 Stress-70 protein, mitochondrial
90 IPI00014398 FHL1   four and a half LIM domains protein 1 isoform 5  ----- 0.09 0.09 35494  ----- 71 52  ----- 1 1 Q13642 Four and a half LIM domains protein 1
91 IPI00020008 NEDD8  NEDD8  ----- 0.87 0.37 9066  ----- 163 136  ----- 3 2 Q15843 NEDD8
92 IPI00218466 SEC61A1  cDNA FLJ59739, highly similar to Protein transport protein Sec61 subunit alpha isoform 1  ----- 0.26 0.06 53371  ----- 216 43  ----- 4 1 B4DR60 Protein transport protein Sec61 subunit alpha isoform 0
93 IPI00031691 RPL9   60S ribosomal protein L9  ----- 0.15 0.31 21964  ----- 49 101  ----- 1 2 P32969 60S ribosomal protein L9
94 IPI00293464 DDB1  DNA damage-binding protein 1  ----- 0.05 0.02 128142  ----- 71 41  ----- 2 1 Q16531 DNA damage-binding protein 1
95 IPI00302592 FLNA   Isoform 2 of Filamin-A  ----- 0.09 0.1 282581  ----- 292 285  ----- 8 9 Q60FE6 Filamin A
96 IPI00328354 MAGED1   Isoform 1 of Melanoma-associated antigen D1  ----- 0.04 0.04 86221  ----- 50 80  ----- 1 1 Q9Y5V3 Melanoma-associated antigen D1
97 IPI00446294 TOM1L2   Isoform 1 of TOM1-like protein 2  ----- 0.06 0.06 55864  ----- 47 66  ----- 1 1 Q6ZVM7 TOM1-like protein 2
98 IPI00790498 PSMD11  PSMD11 Protein  ----- 2.14 2.7 18111  ----- 261 289  ----- 8 9  -  -
99 IPI01019113 TUBB  Tubulin beta chain  ----- 3.31 3.31 50095  ----- 1010 1067  ----- 26 26 P07437 Tubulin beta chain
100 IPI00000643 BAG2  BAG family molecular chaperone regulator 2 0.13  -----  ----- 23928 46  -----  ----- 1  -----  ----- O95816 BAG family molecular chaperone regulator 2
101 IPI00008455 MYO6  Isoform 2 of Myosin-VI 0.02  -----  ----- 147324 49  -----  ----- 1  -----  ----- Q9UM54 Unconventional myosin-VI
102 IPI00009146 TRAFD1  TRAF-type zinc finger domain-containing protein 1 0.05  -----  ----- 66226 55  -----  ----- 1  -----  ----- O14545 TRAF-type zinc finger domain-containing protein 1
103 IPI00019472 SLC1A5  Neutral amino acid transporter B(0) 0.05  -----  ----- 57018 53  -----  ----- 1  -----  ----- Q15758 Neutral amino acid transporter B(0)
104 IPI00021263 YWHAZ  14-3-3 protein zeta/delta 0.38  -----  ----- 27899 100  -----  ----- 3  -----  ----- P63104 14-3-3 protein zeta/delta
105 IPI00022891 SLC25A4  ADP/ATP translocase 1 0.2  -----  ----- 33271 89  -----  ----- 2  -----  ----- P12235 ADP/ATP translocase 1
106 IPI00027255 MYL6B  Myosin light chain 6B 0.14  -----  ----- 22864 49  -----  ----- 1  -----  ----- P14649 Myosin light chain 6B
107 IPI00027626 CCT6A  T-complex protein 1 subunit zeta 0.11  -----  ----- 58444 56  -----  ----- 1  -----  ----- P40227 T-complex protein 1 subunit zeta
108 IPI00028635 RPN2  Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 0.05  -----  ----- 69355 49  -----  ----- 1  -----  ----- P04844 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2
109 IPI00030243 PSME3  Isoform 1 of Proteasome activator complex subunit 3 0.11  -----  ----- 29602 51  -----  ----- 1  -----  ----- P61289 Proteasome activator complex subunit 3
110 IPI00030770 PSMG1  Isoform 1 of Proteasome assembly chaperone 1 0.09  -----  ----- 33631 44  -----  ----- 1  -----  ----- O95456 Proteasome assembly chaperone 1
111 IPI00075248 CALM3;CALM2;CALM1   Calmodulin 0.19  -----  ----- 16827 40  -----  ----- 0  -----  ----- P62158 Calmodulin
112 IPI00149276 BRE  Isoform 1 of BRCA1-A complex subunit BRE 0.07  -----  ----- 47572 48  -----  ----- 1  -----  ----- Q9NXR7 BRCA1-A complex subunit BRE
113 IPI00218343 TUBA1C  Tubulin alpha-1C chain 3  -----  ----- 50548 1045  -----  ----- 26  -----  ----- Q9BQE3 Tubulin alpha-1C chain
114 IPI00294501 DHCR7   7-dehydrocholesterol reductase 0.06  -----  ----- 55195 43  -----  ----- 1  -----  ----- Q9UBM7 7-dehydrocholesterol reductase
115 IPI00295772 CYP51A1   lanosterol 14-alpha demethylase isoform 1 0.05  -----  ----- 57641 60  -----  ----- 1  -----  ----- Q16850 Lanosterol 14-alpha demethylase
116 IPI00553169 FLNA  Uncharacterized protein 0.08  -----  ----- 248165 189  -----  ----- 5  -----  ----- A6NDY9 Filamin A
117 IPI00645452 TUBB Uncharacterized protein 3.02  -----  ----- 48135 980  -----  ----- 27  -----  ----- B7ZAK1 cDNA, FLJ79215, highly similar to Tubulin beta-7 chain
118 IPI00966795 HSPA9  Uncharacterized protein 0.5  -----  ----- 6805 53  -----  ----- 1  -----  ----- D6RA73 Stress-70 protein, mitochondrial
119 IPI00000875 EEF1G highly similar to Elongation factor 1-gamma  ----- 0.06  ----- 56456  ----- 40  -----  ----- 1  ----- B4DTG2 Elongation factor 1-gamma
120 IPI00013808 ACTN4  Alpha-actinin-4  ----- 0.03  ----- 105245  ----- 41  -----  ----- 1  ----- O43707 Alpha-actinin-4
121 IPI00014311 CUL2 Cullin-2  ----- 0.07  ----- 87554  ----- 60  -----  ----- 2  ----- Q13617 Cullin-2
122 IPI00015671 TUBAL3  Isoform 1 of Tubulin alpha chain-like 3  ----- 0.13  ----- 50675  ----- 115  -----  ----- 2  ----- A6NHL2 Tubulin alpha chain-like 3
123 IPI00022744 CSE1L Isoform 1 of Exportin-2  ----- 0.03  ----- 111145  ----- 41  -----  ----- 1  ----- P55060 Exportin-2
124 IPI00094740 RNF31 Isoform 1 of RING finger protein 31  ----- 0.05  ----- 122654  ----- 103  -----  ----- 2  ----- Q96EP0 E3 ubiquitin-protein ligase RNF31
125 IPI00215948 CTNNA1  Isoform 1 of Catenin alpha-1  ----- 0.03  ----- 100693  ----- 81  -----  ----- 1  ----- P35221 Catenin alpha-1
126 IPI00216691 PFN1  Profilin-1  ----- 0.21  ----- 15216  ----- 51  -----  ----- 1  ----- P07737 Profilin-1
127 IPI00217407 UBR2 Isoform 4 of E3 ubiquitin-protein ligase UBR2  ----- 0.03  ----- 203831  ----- 72  -----  ----- 2  ----- Q8IWV8 E3 ubiquitin-protein ligase UBR2
128 IPI00221092 RPS16  40S ribosomal protein S16  ----- 0.43  ----- 16549  ----- 86  -----  ----- 2  ----- P62249 40S ribosomal protein S16
129 IPI00410680 ANKHD1-EIF4EBP3;ANKHD1 Isoform 3 of Ankyrin repeat and KH domain-containing protein 1  ----- 0.05  ----- 64585  ----- 41  -----  ----- 1  ----- Q8IWZ3 Ankyrin repeat and KH domain-containing protein 1
130 IPI00423874 AMFR  E3 ubiquitin-protein ligase AMFR  ----- 0.04  ----- 73747  ----- 39  -----  ----- 1  ----- Q9UKV5 E3 ubiquitin-protein ligase AMFR
131 IPI00456695 PSMD1  Isoform 2 of 26S proteasome non-ATPase regulatory subunit 1  ----- 2.82  ----- 103162  ----- 2134  -----  ----- 46  ----- Q99460 26S proteasome non-ATPase regulatory subunit 1
132 IPI00643152 HSPA1L   highly similar to Heat shock 70 kDa protein 1L  ----- 0.22  ----- 77912  ----- 214  -----  ----- 5  ----- B4DI54 cDNA FLJ56386, highly similar to Heat shock 70 kDa protein 1L
133 IPI00759683 CAV1  Isoform Beta of Caveolin-1  ----- 0.19  ----- 17183  ----- 43  -----  ----- 1  ----- Q03135 Caveolin-1
134 IPI01025580  - Possible J 56 gene segment (Fragment)  ----- 1.75  ----- 2269  ----- 41  -----  ----- 1  ----- A0N4V7 HCG2039797
135 IPI00008524 PABPC1   Isoform 1 of Polyadenylate-binding protein 1  -----  ----- 0.14 70854  -----  ----- 130  -----  ----- 3 P11940 Polyadenylate-binding protein 1
136 IPI00008527 RPLP1  60S acidic ribosomal protein P1  -----  ----- 0.64 11621  -----  ----- 80  -----  ----- 2 P05386 60S acidic ribosomal protein P1
137 IPI00008529 RPLP2  60S acidic ribosomal protein P2  -----  ----- 0.64 11658  -----  ----- 99  -----  ----- 2 P05387 60S acidic ribosomal protein P2
138 IPI00008530 RPLP0  60S acidic ribosomal protein P0  -----  ----- 0.42 34423  -----  ----- 123  -----  ----- 4 P05388 60S acidic ribosomal protein P0
139 IPI00012442 G3BP1  Ras GTPase-activating protein-binding protein 1  -----  ----- 0.06 52189  -----  ----- 69  -----  ----- 1 Q13283 Ras GTPase-activating protein-binding protein 1
140 IPI00013415 RPS7  40S ribosomal protein S7  -----  ----- 0.31 22113  -----  ----- 61  -----  ----- 2 P62081 40S ribosomal protein S7
141 IPI00013683 TUBB3;MC1R  Tubulin beta-3 chain  -----  ----- 1.05 50856  -----  ----- 419  -----  ----- 14 Q13509 Tubulin beta-3 chain
142 IPI00013917 RPS12 40S ribosomal protein S12  -----  ----- 0.22 14905  -----  ----- 62  -----  ----- 1 P25398 40S ribosomal protein S12
143 IPI00021405 LMNA Isoform A of Prelamin-A/C  -----  ----- 0.39 74380  -----  ----- 188  -----  ----- 7 P02545 Prelamin-A/C
144 IPI00021428 ACTA1  Actin, alpha skeletal muscle  -----  ----- 1.54 42366  -----  ----- 409  -----  ----- 13 P68133 Actin, alpha skeletal muscle
145 IPI00024933 RPL12 Isoform 1 of 60S ribosomal protein L12  -----  ----- 0.64 17979  -----  ----- 95  -----  ----- 3 P30050 60S ribosomal protein L12
146 IPI00026087 BANF1  Barrier-to-autointegration factor  -----  ----- 0.32 10280  -----  ----- 46  -----  ----- 1 O75531 Barrier-to-autointegration factor
147 IPI00026302 RPL31  60S ribosomal protein L31  -----  ----- 0.5 14454  -----  ----- 90  -----  ----- 2 P62899 60S ribosomal protein L31
148 IPI00027252 PHB2  Prohibitin-2  -----  ----- 0.09 33276  -----  ----- 44  -----  ----- 1 Q99623 Prohibitin-2
149 IPI00031562 HIST3H2A  Histone H2A type 3  -----  ----- 0.86 14113  -----  ----- 138  -----  ----- 3 Q7L7L0 Histone H2A type 3
150 IPI00031801 CSDA  Isoform 1 of DNA-binding protein A  -----  ----- 0.08 40066  -----  ----- 86  -----  ----- 1 P16989 DNA-binding protein A
151 IPI00072918 COL6A3  Uncharacterized protein  -----  ----- 0.02 323698  -----  ----- 89  -----  ----- 2 E7ENL6 Collagen alpha-3(VI) chain
152 IPI00178352 FLNC Isoform 1 of Filamin-C  -----  ----- 0.01 293407  -----  ----- 51  -----  ----- 1 Q14315 Filamin-C
153 IPI00215965 HNRNPA1   Isoform A1-B of Heterogeneous nuclear ribonucleoprotein A1  -----  ----- 0.08 38837  -----  ----- 58  -----  ----- 1 P09651 Heterogeneous nuclear ribonucleoprotein A1
154 IPI00219153 RPL22  60S ribosomal protein L22  -----  ----- 0.22 14835  -----  ----- 51  -----  ----- 1 P35268 60S ribosomal protein L22
155 IPI00220278 MYL9 Myosin regulatory light polypeptide 9  -----  ----- 3.46 19871  -----  ----- 388  -----  ----- 10 P24844 Myosin regulatory light polypeptide 9
156 IPI00220403 HIST1H2BB  Histone H2B type 1-B  -----  ----- 0.87 13942  -----  ----- 155  -----  ----- 3 P33778 Histone H2B type 1-B
157 IPI00220740 NPM1  Isoform 2 of Nucleophosmin  -----  ----- 0.5 29617  -----  ----- 147  -----  ----- 4 P06748 Nucleophosmin
158 IPI00335168 MYL6  Isoform Non-muscle of Myosin light polypeptide 6  -----  ----- 4.63 17090  -----  ----- 326  -----  ----- 10 P60660 Myosin light polypeptide 6
159 IPI00419880 SNORD73A;RPS3A  40S ribosomal protein S3a  -----  ----- 0.1 30154  -----  ----- 65  -----  ----- 1 P61247 40S ribosomal protein S3a
160 IPI00444262 NCL  highly similar to Nucleolin  -----  ----- 0.52 65979  -----  ----- 412  -----  ----- 9 Q6ZS99 cDNA FLJ45706 fis, clone FEBRA2028457, highly similar to Nucleolin 
161 IPI00005705 PPP1CC  Isoform Gamma-1 of Serine/threonine-protein phosphatase PP1-gamma catalytic subunit 0.08 0.08  ----- 37701 57 82  ----- 1 1  ----- P36873 Serine/threonine-protein phosphatase PP1-gamma catalytic subunit
162 IPI00006482 ATP1A1  Isoform Long of Sodium/potassium-transporting ATPase subunit alpha-1 0.03 0.06  ----- 114135 96 63  ----- 1 2  ----- P05023 Sodium/potassium-transporting ATPase subunit alpha-1
163 IPI00008603 ACTA2  Actin, aortic smooth muscle 1.05 1.2  ----- 42381 279 284  ----- 10 10  ----- P62736 Actin, aortic smooth muscle
164 IPI00022200 COL6A3  Isoform 1 of Collagen alpha-3(VI) chain 0.04 0.04  ----- 345167 162 175  ----- 4 4  ----- P12111 Collagen alpha-3(VI) chain
165 IPI00182289 RPS29  40S ribosomal protein S29 0.49 0.49  ----- 6900 56 64  ----- 1 1  ----- P62273 40S ribosomal protein S29
166 IPI00217831 ANKRD13A  Ankyrin repeat domain-containing protein 13A 0.09 0.05  ----- 67976 86 47  ----- 2 1  ----- Q8IZ07 Ankyrin repeat domain-containing protein 13A
167 IPI00791265 SNORD54;RPS20 Uncharacterized protein 0.49 1.23  ----- 6881 50 89  ----- 1 2  ----- E5RJX2 40S ribosomal protein S20
168 IPI00019502 MYH9  Isoform 1 of Myosin-9 0.1  ----- 1.51 227646 340  ----- 2994 7  ----- 66 P35579 Myosin-9
Identified in unstimulated and poly(I:C) stimulated cells
Identified in both IL-1 and poly(I:C) stimulated cells
Identified only in unstimulated cells
Identified only in IL-1 stimulated cells
Identified only in poly(I:C) stimulated cells
Idfentified in unstimulated and IL-1 stimulated cells
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169 IPI00026271 RPS14 40S ribosomal protein S14 0.2  ----- 0.43 16434 59  ----- 93 1  ----- 2 P62263 40S ribosomal protein S14
170 IPI00033494 MYL12B  Myosin regulatory light chain 12B 0.16  ----- 5.99 19824 66  ----- 584 1  ----- 13 O14950 Myosin regulatory light chain 12B
171 IPI00299608 PSMD1  Isoform 1 of 26S proteasome non-ATPase regulatory subunit 1 2.45  ----- 2.35 106795 1808  ----- 1909 45  ----- 43 Q99460 26S proteasome non-ATPase regulatory subunit 1
172 IPI00303476 ATP5B  ATP synthase subunit beta, mitochondrial 0.06  ----- 0.11 56525 49  ----- 89 1  ----- 2 P06576 ATP synthase subunit beta, mitochondrial
173 IPI00418471 VIM Vimentin 0.25  ----- 2.11 53676 100  ----- 621 4  ----- 20 P08670 Vimentin
174 IPI00450975 RPS16  Uncharacterized protein 0.67  ----- 0.67 17267 102  ----- 120 3  ----- 3 Q6IPX4 40S ribosomal protein S16
175 IPI00797373 DOCK8  Isoform 1 of Dedicator of cytokinesis protein 8 0.01  ----- 0.01 240886 53  ----- 42 1  ----- 1 Q8NF50 Dedicator of cytokinesis protein 8
176 IPI00968128 RPL9  Protein 0.15  ----- 0.32 21671 45  ----- 81 1  ----- 2  -  - 
Modified peptides Ubiquitin ? K # 
MQIFVK(GG)TLTGK
LIFAGK(GG)QLEDGR
TLSDYNIQK(GG)ESTLHLVLR
TLTGK(GG)TITLEVEPSDTIENVK
LIFAGK(GG)QLEDGRTLSDYNIQK
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